NKTR - NEKTAR THERAPEUTICS
IEX Last Trade
0.92
0.004 0.424%
Share volume: 2,528
Last Updated: Fri 27 Dec 2024 04:30:04 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.05%
PREVIOUS CLOSE
CHG
CHG%
$0.92
0.00
0.43%
Fundamental analysis
21%
Profitability
0%
Dept financing
17%
Liquidity
75%
Performance
30%
Performance
5 Days
0.81%
1 Month
-15.16%
3 Months
-18.22%
6 Months
-15.94%
1 Year
74.58%
2 Year
-57.78%
Key data
Stock price
$0.92
DAY RANGE
$0.91 - $0.95
52 WEEK RANGE
$0.52 - $1.93
52 WEEK CHANGE
$64.46
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Howard W. Robin
Region: US
Website: nektar.com
Employees: 220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: nektar.com
Employees: 220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinomas of the head and neck, and adjuvant melanoma. It is also developing NKTR-358, a cytokine Treg stimulant, in phase 2 clinical trial for the treatment of systemic lupus erythematosus
Recent news